Flush FTSE 100 giant Astrazeneca to give more back to shareholders with dividend hike April 11, 2024 AstraZeneca will increase its annual dividend for the year by $0.20 (16p) to $3.10 (£2.47) per share
Are LVMH, Nestle, L’Oreal and Hermes Europe’s alternative to Microsoft, Apple, Nvidia and Tesla? April 9, 2024 Much has been made of the 'Magnificent Seven' tech stocks - Meta, Apple, Amazon. Alphabet, Microsoft, Nvidia and Tesla - which have dominated the US market amid a boom in demand for AI and, until recently, more optimism over potential interest rate cuts.
Covid-19 anniversary: How have GSK and Astrazeneca fared since? March 23, 2024 The Covid-19 pandemic also ignited interest in the pharmaceutical sector. Even before the UK went into lockdown, the sector was looking for ways to fight the virus.
Astrazeneca expands cancer treatment stable with purchase of Canada-based Fusion March 19, 2024 The Cambridge-based pharma firm is paying $2bn cash up front as part of the deal
Astrazeneca: Pharma giant snaps up rare disease biotech firm Amoylt March 14, 2024 The acquisition, which is meant to "bolster" Astrazenca's rare disease arm Alexion, brings with it a Phase III investigational therapeutic peptide meant for hypoparathyroidism
Spring Budget 2024: Astrazeneca to invest £650m in Cambridge and Liverpool March 6, 2024 AstraZeneca is to invest £650m in the UK, Chancellor Jeremy Hunt has announced in his Spring Budget.
FTSE 100: London creeps into the green, Currys soars as takeover battle looks likely February 19, 2024 On the FTSE 100, Astrazeneca rose to the top of the index after its Tagrisso drug received positive clinical trial results.
Astrazeneca share price rises as Tagrisso drug shows ‘highly impactful’ results in lung cancer trial February 19, 2024 Results from Tagrisso's Phase III trial showed a "statistically significant and highly clinically meaningful improvement" in progression-free survival.
FTSE 100 close: London dragged lower by Astrazeneca, DS Smith soars after takeover rumours February 8, 2024 Shares in Astrazeneca, the biggest company listed in London, dropped 6.3 per cent even after reporting an increase in revenue in 2023.
Astrazeneca shares plummet despite FTSE 100’s biggest firm posting revenue boost February 8, 2024 Astrazeneca said excluding coronavirus, its total sales increased by 15 per cent, as its chief executive predicted "double digit earnings" for the year ahead.